Janus 1 Trial | Jakafi ruxolitinib
Learn more about the Janus I trial a phase 3 study evaluating capecitabine with or without ruxolitinib in patients with advanced or metastatic adenocarcinoma of the pancreas.
Janus 1 trial, janus 1 clinical trial, JAK INhibition with Ruxolitinib, adenocarcinoma of the pancreas, Ruxolitinib and Capecitabine, advanced pancreatic adenocarcinoma, or metastatic pancreatic adenocarcinoma.
Is this your site? Certify your site and update informations
